Healthcare Industry News: microfluidics
News Release - June 1, 2016
Aviana Molecular Technologies welcomes William J. Link, Ph.D. as Chairman of its Board of DirectorsORLANDO, Fla., June 1, 2016 -- (Healthcare Sales & Marketing Network) -- Aviana Molecular Technologies, LLC, a development-stage diagnostic company, is very pleased to announce the appointment of Dr. Bill Link as Chairman of its Board of Directors. Dr. Link is a leader in the healthcare industry. He is a Managing Director of Versant Ventures, a distinguished venture capital firm focused on healthcare. Dr. Link has specialized in early-stage investing in medical devices. Prior to co-founding Versant Ventures in 1999, Dr. Link was a general partner at Brentwood Venture Capital. With more than two decades of operations experience in the healthcare industry, he has a proven record of building and managing large, successful medical product companies.
Aviana Molecular Technologies has developed a cutting edge platform founded on the innovative adaptation of surface acoustic wave (SAW) sensors, commonly used in cellphone communications, into a novel class of biosensors. The platform leverages the latest developments in cellular communications, semiconductor electronics, microfluidics and manufacturing methods to create a unique point-of-care diagnostic platform that is portable, cost-effective, and versatile.
"Dr. Link brings his immense experience and expertise to bear on the Company's innovative technologies. Dr. Link's shepherding of technologies to successful completion will be critical to the Company's success" said Dr. Vanaja V. Ragavan, President and CEO.
"I have known Dr. Link for over 30 years and am very pleased that he has agreed to join the Board of Directors" said Edward Peterson, the Company's current Chairman of the Board of Directors.
About Aviana Molecular Technologies
Aviana Molecular Technologies (http://www.avianamolecular.com/) (AMT) is a development stage diagnostic company working on an innovative, highly sensitive, and user-friendly platform technology, with an initial interest in developing a point-of-care (POC) diagnostic. Aviana's technology is simple, adaptable, and can be used for a point of care diagnosis for any number of biomarkers or infections. The platform can be used in both highly sophisticated health systems but also in resource-limited environments. Aviana believes that its technology can fill unmet medical needs in the U.S. and around the world, where POC diagnosis can positively impact human health.
Source: Aviana Molecular Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.